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DDiscussion
Dr Leonard Girardi (New York, NY). The Stanford group once
again should be congratulated on their continued commitment to
the analysis and improvement of V-SARR. In the 154 patients
they included in this series, 62% had both 1- and 5-year follow-
up echocardiography imaging; 43% of these had aortic insuffi-
ciency (AI); 85%, as you said, never progressed any further than
mild AI. Of the 5 or 6 who did progress, once they get to 2+ or
moderate AI, again, a gratifying number, 80% went no further
and only 1 subsequently went on to require aortic valve
replacement.
In the patients who underwent reoperation, 4 of the 96, an
outstanding rate, 2 additional patients required surgery for valve
deterioration. One person developed endocarditis. So only 1 of
these patients went from mild AI at 1 year to surgery in the future.
The 2 patients who required surgery without endocarditis quickly
experienced significant AI.
The indications for this procedure have continuously expanded
over the years to an increasingly complex and diverse patient
population. No longer are we offering this operation just to young
patients with ascending aortic aneurysms, TAVs, and minimal AI.
This collection of patients certainly represents what I would
think is a ‘‘real world’’ look at aortic root replacement and aortic
valve-sparing surgery. It includes patients with bicuspid valves,
advanced CTDs, a few aortic dissections, and reoperations. Fifteen
percent of their patients had severe AI at the time of surgery.
Despite Dr Miller’s extensive experience with this surgery and
other root replacement, 43% had AI at the time of 1-year
follow-up; 17% had mild AI before they even left the hospital,
and this is in extremely experienced hands.
So, again, it is not surprising to me that these patients have AI.
These data reassure us that just because you have AI at 1 year,
even if it’s moderate, all is not lost. This should be reassuring to
not only the surgeons performing the surgery but also the cardiolo-
gists following them and, most important, the patient. As patients
get their echocardiography reports and hear that they have AI,
they can go into a tailspin by thinking a reoperation is right
around the corner. That clearly is not the case and to me the most
important result of this study. I have a number of questions for you.
On your more advanced multivariate analysis, the only risk
factor that really was significantly predictive of the need for
reoperation was aortic valve repair. I know at least for us at
Cornell, one of the problems we have is trying to figure out who
really needs valve repair and who doesn’t. I question sometimes
whether we do too many of them and whether we are actuallyThe Journal of Thoracic and Cadoing more harm than good. What techniques do you use at
Stanford to try to sort out who could benefit from a valve repair
and those we should leave alone? Do you have a way to know
who they are?
Dr Stephens. Thank you, Dr Girardi, for your excellent ques-
tions. Regarding aortic valve repair, we often don’t know whether
we are going to need to add any cusp repair until that graft is sutured
down and the final neo-annular geometry can be appreciated; then
we see if we have induced any new prolapse or there was prolapse
present before the graft that needs attention.We do not always know
ahead of time which patients are going to need aortic cusp repairs.
That said, yes, we continue to do valve-sparing procedures in
patients who need cusp repairs. I think it comes down to, as
Dr David continues to say, the quality of the cusps. If the cusps
are of good quality, and, in particular in the patients with bicuspid
valves, have minimal fibrosis or calcification, then we feel we can
achieve a durable repair and proceed. This is based on the
analysis of the entire Stanford experience that was presented at
the American Association for Thoracic Surgery last year in which
aortic valve repair was not a predictor of reoperation or recurrent
AR. So we have continued to do aortic valve repair, and, as you
saw, most frequently it is cusp free margin shortening. The analysis
of the entire Stanford experience is consistent with other large
series in which aortic valve repair was not a significant predictor
of AR recurrence or reoperation.
Dr Girardi. After you have reimplanted the valve and you look
down through and see obvious prolapse, you sort of know it when
you see it. But other than those patients, are you waiting until the
patient comes off bypass to figure out who needs valve repair? Did
you re-clamp and re-pledge, because a lot of these patients have
had long crossclamp times, long pump runs, and another period
of myocardial ischemia might not be the right thing. Your data
would suggest that coming off bypass with a little bit of AI, or
maybe even 1-1/2+ AI, is not such a bad thing. We could leave
them with that rather than taking the risk of another period of
ischemia. Is that how it is done?
Dr Stephens. To address your question of what our limit is in
terms of AR coming out of the operating room, we do not leave
with anything more than with anything more than trace (or mild
at the worst) AR; we always ‘‘stress test’’ the valve by increasing
the systolic blood pressures to at least 150 mm Hg to see whether
the valve leaks. Luckily, in the more than 300 cases that Dr Miller
has done since 1993, he has never had to re-crossclamp to re-repair
a valve or convert to valve replacement on the table.
Dr Girardi. So experience is more important than anything. Is
that what you are saying?
Dr Stephens. Absolutely.
Dr Girardi. Of the patients who did fail, 2 of them had a lot of
AI fairly early on, within 1 year, and if you look at the data, which
were not presented here because of time constraints, although
preoperative annular diameter was not found to be predictive of
failure, 2 of those patients had a big annulus. One was a 35- or
34-mm annulus in an 11-year-old, and another had an annulus
that was in excess of 40 mm. So it just may be that there is too
small of a number to predict valve failure.
If you had to do that again, would those patients still get a
valve-sparing root, or are there limits to what you will do? As
you said, a CVG after coming off bypass has not been necessary,rdiovascular Surgery c Volume 147, Number 1 177
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Dbut do you see people in the operating room and say, this isn’t
going to work?
Dr Stephens. Two points with regard to those excellent
questions, the first regarding reoperation. We had 4 reoperations;
1 case was the 11-year-old boy with MFS you mentioned with a
huge annulus, very poor tissue integrity, and who also needed a
very complicated mitral repair; Dr Miller in hindsight feels saving
these valves was a judgment error in this particular patient.
Another patient who required reoperation had a BAV and 4+ AR
preoperatively; gross prolapse of the fused left-right coronary
cusp was due to rupture of truncal-valve type of suspensory chor-
dae in the left-right commissure. He received commissural neo-
suspensory chords using polytetrafluoroethylene (Gore-Tex; WL
Gore & Associates Inc, Flagstaff, Ariz) suture that pulled out of
the tissue after 20 months, leading to acute recurrent 4+ AR. We
have been more hesitant in light of that particular patient to use
commissural neo-suspensory polytetrafluoroethylene (Gore-Tex)
chords. We learned hard lessons from both of these patients.
Dr Tirone David (Toronto, Ontario, Canada). I don’t know
howmany of you know, but Elizabeth Stephens is a surgical intern.
I have to commend her to be brave enough to stand in an audience
of mostly men and present us her study.
Elizabeth, aortic valve repair is nodifferent thanmitral valve repair
and likely the single most important thing, more important than how
little the valve is leaking in the operating room is morphology of the
cusps when you finish the reimplantation or remodeling. As in mitral
valve repair, we talk about leaflets coaptation area, and the coaptation
has to bewithin the ventricle. In the aortic valve, the coaptation has to
be within the aortic root. So if the cusps are coapting 4 to 6 mm, and
they are 8 mm inside the aortic root, and there is mild AI, reassure
yourself that things will alright for the next 20 years. We have done
that, and they seldom fail.
If at the end of the operation the cusps coapt at the level of the
annulus or below, it is usually bad news because they will come178 The Journal of Thoracic and Cardiovascular Surgback with AI. This has been our experience with tricuspid aortic
valves. I am a late comer in BAV reimplantation, but Dr Sch€afers
has more experience than anybody else, and he may say the same
for BAVs. Did you look at morphology of the cusps and try to
correlate it with AI?
Dr Stephens. We have not looked at morphology.
Dr David. But you have the data, don’t you; you have the
intraoperative echocardiograms?
Dr Stephens. Yes.
DrHans-Joachim Sch€afers (Homburg/Saar, Germany). I would
like to repeat the topic that Tirone has started, that is, valve
morphology. Multiple series have shown that if you achieve normal
valve morphology, the valve will be stable at the end of the opera-
tion. There are essentially 2 ways of assessing valve morphology:
One is eyeballing, and the other is actual measurement, such
as measurement of effective height. What was the primary
parameter? Was it eyeballing or some objective measurement, and
if so, what?
Dr Stephens. In general, we aim for a goal of 5 to 9 mm of
coaptation height (or ‘‘effective coaptation height’’ as you define
it, Dr Sch€afers); as Dr David alluded to, that coaptation zone has
to be relatively high within the graft, but we have not objectively
measured that variable. I don’t know if Dr Miller can comment
on that.
Dr Miller. Hans-Joachim, we eyeball it and do not have your
little J-shaped tool to directly measure ‘‘effective coaptation
length.’’ Maybe we should. We have tried to estimate coaptation
zone height from the postoperative TTEs, but that is probably
not terribly accurate. I agree that the geometric principles that Tir-
one David and you told us about are important.
Thank you, Tirone, for pointing out that Elizabeth Stephens is a
postgraduate year 1 (intern) at Columbia. If I were an intern
up here in front of this audience, I’d be in supraventricular
tachycardia with a heart rate over 200.ery c January 2014
